Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 561 - 568 of 12089 results

The Biden Administration Issues National Security Memorandum on AI – AI: The Washington Report
November 1, 2024| Article| Viewpoint

Telephone and Texting Compliance News — October 2024
October 31, 2024| Article| Viewpoint

The Importance of Technical Diligence on Source Code During Asset Acquisitions
October 31, 2024| News

Regional Challenges in Regulating Medical Product AI
October 30, 2024| Webinar| Viewpoint

Stakeholders Raise 340B Concerns in Medicaid Drug Rebate Program Final Rule; CMS, With Hands Tied, Shrugs
October 30, 2024| Blog| Viewpoint

Telephone and Texting Compliance News: Litigation Update — Will the Supreme Court Revive TCPA Fax Cases and Deliver Another Blow to the FCC?
October 30, 2024| Article| Viewpoint

Consumer Privacy Laws are Taking Effect Across the Nation – Are You Ready?
October 30, 2024| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts

Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|

Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
